Applying Serum Cytokine Levels to Predict Pain Severity in Cancer Patients

References

• Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69(1–2):1–18. doi:10.1016/s0304-3959(96)03267-8
   PubMed Web of Science ®Google Scholar
• Christo PJ, Mazloomdoost D. Cancer pain and analgesia. Ann N Y Acad Sci. 2008;1138:278–298. doi:10.1196/annals.1414.033
   PubMed Web of Science ®Google Scholar
• Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(16):1647–1654. doi:10.1200/JCO.2013.51.7219
   PubMed Web of Science ®Google Scholar
• Chow E, Hird A, Zhang L, et al. Change in urinary markers of osteoclast activity following palliative radiotherapy for bone metastases. Clin Oncol. 2009;21(4):336–342. doi:10.1016/j.clon.2009.01.013
   Web of Science ®Google Scholar
• Chow E, Deangelis C, Chen BE, et al. Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC.20U). Radiother Oncol. 2015;115(1):141–148. doi:10.1016/j.radonc.2015.02.025
   Web of Science ®Google Scholar
• Gardner K, Laird BJA, Fallon MT, Sande TA. A systematic review examining clinical markers and biomarkers of analgesic response to radiotherapy for cancer-induced bone pain. Crit Rev Oncol Hematol. 2019;133:33–44. doi:10.1016/j.critrevonc.2018.10.008
   Web of Science ®Google Scholar
• Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR. Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity. Lancet (London, England). 2000;355(9213):1428–1429. doi:10.1016/s0140-6736(00)02144-9
   Web of Science ®Google Scholar
• Vendrell I, Macedo D, Alho I, Dionísio MR, Costa L. Treatment of cancer pain by targeting cytokines. Mediators Inflamm. 2015;2015:1–11. doi:10.1155/2015/984570
   Web of Science ®Google Scholar
• Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003;97(11):2919–2925. doi:10.1002/cncr.11382
   PubMed Web of Science ®Google Scholar
• Lippitz BE, Harris RA. Cytokine patterns in cancer patients: a review of the correlation between interleukin 6 and prognosis. Oncoimmunology. 2016;5(5):e1093722. doi:10.1080/2162402X.2015.1093722
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–e228. doi:10.1016/S1470-2045(12)70582-X
   PubMed Web of Science ®Google Scholar
• Ø P, Laird B, Aass N, et al. The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer. PLoS One. 2017;12(5):e0177620. doi:10.1371/journal.pone.0177620
   Web of Science ®Google Scholar
• Panis C, Pavanelli WR. Cytokines as mediators of pain-related process in breast cancer. Mediators Inflamm. 2015;2015:1–6. doi:10.1155/2015/129034
   Web of Science ®Google Scholar
• Kuchuk I, Beaumont JL, Clemons M, Amir E, Addison CL, Cella D. Effects of de-escalated bisphosphonate therapy on the functional assessment of cancer therapy-bone pain, brief pain inventory and bone biomarkers. J Bone Oncol. 2013;2(4):154–157. doi:10.1016/j.jbo.2013.07.004
   Web of Science ®Google Scholar
• Addison CL, Bouganim N, Hilton J, et al. A Phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat. 2014;144(3):615–624. doi:10.1007/s10549-014-2906-x
   Web of Science ®Google Scholar
• Niculescu AB, Le-Niculescu H, Levey DF, et al. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019;24(4):501–522. doi:10.1038/s41380-018-0345-5
   PubMed Web of Science ®Google Scholar
• Panis C, Victorino VJ, Herrera ACSA, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. 2012;133(3):881–888. doi:10.1007/s10549-011-1851-1
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6(6):e1792. doi:10.1038/cddis.2015.162
   PubMed Web of Science ®Google Scholar
• Nicol LSC, Thornton P, Hatcher JP, et al. Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain. Pain. 2018;159(3):550–559. doi:10.1097/j.pain.0000000000001130
   Web of Science ®Google Scholar
• Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008;8(7):533–544. doi:10.1038/nri2356
   PubMed Web of Science ®Google Scholar
• Schweizerhof M, Stösser S, Kurejova M, et al. Hematopoietic colony–stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med. 2009;15(7):802–807. doi:10.1038/nm.1976
   PubMed Web of Science ®Google Scholar
• Abbas AK, Trotta E, Simeonov RD, Marson A, Bluestone JA. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):eaat1482. doi:10.1126/sciimmunol.aat1482
   PubMed Web of Science ®Google Scholar
• Song P, Zhao ZQ, Liu XY. Expression of IL-2 receptor in dorsal root ganglion neurons and peripheral antinociception. Neuroreport. 2000;11(7):1433–1436. doi:10.1097/00001756-200005150-00016
   PubMed Web of Science ®Google Scholar
• Yao M-Z, Gu J-F, Wang J-H, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience. 2002;112(2):409–416. doi:10.1016/S0306-4522(02)00078-7
   Web of Science ®Google Scholar
• Aielli F, Ponzetti M, Rucci N. Bone metastasis pain, from the bench to the bedside. Int J Mol Sci. 2019;20:2. doi:10.3390/ijms20020280
   Web of Science ®Google Scholar
• de Oliveira CMB, Sakata RK, Issy AM, Gerola LR, Salomão R. Cytokines and pain. Rev Bras Anestesiol. 2011;61(2):255–259, 260–265, 137–142. doi:10.1016/S0034-7094(11)70029-0
   Web of Science ®Google Scholar
• Sun C, Zhang J, Chen L, et al. IL-17 contributed to the neuropathic pain following peripheral nerve injury by promoting astrocyte proliferation and secretion of proinflammatory cytokines. Mol Med Rep. 2017;15(1):89–96. doi:10.3892/mmr.2016.6018
   PubMed Web of Science ®Google Scholar
• Chen I-F, Khan J, Noma N, et al. Anti-nociceptive effect of IL-12p40 in a rat model of neuropathic pain. Cytokine. 2013;62(3):401–406. doi:10.1016/J.CYTO.2013.03.021
   Web of Science ®Google Scholar
• Hao S, Mata M, Glorioso JC, Fink DJ. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain. 2006;2:1744-8069-2-6. doi:10.1186/1744-8069-2-6
   Web of Science ®Google Scholar
• Bobinski F, Teixeira JM, Sluka KA, Santos ARS. Interleukin-4 mediates the analgesia produced by low-intensity exercise in mice with neuropathic pain. Pain. 2018;159(3):437–450. doi:10.1097/j.pain.0000000000001109
   Web of Science ®Google Scholar
• Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. doi:10.3389/fimmu.2018.00847
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218–1222. doi:10.1172/JCI28508
   PubMed Web of Science ®Google Scholar
• Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303–1309. doi:10.1093/intimm/dxp102
   PubMed Web of Science ®Google Scholar
• Starkweather AR, Lyon DE, Schubert CM. Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs. 2013;15(2):234–241. doi:10.1177/1099800411425857
   Web of Science ®Google Scholar
• Laird BJA, Scott AC, Colvin LA, et al. Cancer pain and its relationship to systemic inflammation: an exploratory study. Pain. 2011;152(2):460–463. doi:10.1016/j.pain.2010.10.035
   PubMed Web of Science ®Google Scholar
• Coleman RE. Impact of bone-targeted treatments on skeletal morbidity and survival in breast cancer. Oncology (Williston Park). 2016;30(8):695–702.
   Web of Science ®Google Scholar
• Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69(1):35–43. doi:10.1159/000087286
   Web of Science ®Google Scholar
• Hendriks LEL, Hermans BCM, van den Beuken-van Everdingen MHJ, Hochstenbag MMH, Dingemans A-MC. Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: a systematic review. J Thorac Oncol off Publ Int Assoc Study Lung Cancer. 2016;11(2):155–173. doi:10.1016/j.jtho.2015.10.001
   Google Scholar
• Sorge RE, Totsch SK. Sex differences in pain. J Neurosci Res. 2017;95(6):1271–1281. doi:10.1002/jnr.23841
   PubMed Web of Science ®Google Scholar
• Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626–638. doi:10.1038/nri.2016.90
   PubMed Web of Science ®Google Scholar